The IMpower 150 trial demonstrated an improved PFS and OS with atezolizumab (A; anti-PD-L1 antibody) + bevacizumab (B; anti-VEGF-A antibody) + carboplatin (C) + paclitaxel (P) (ABCP) compared to BCP (median PFS 8.3 vs. 6.8 mos, HR 0.62, p < 0.001 and median OS 19.2 vs. 14.7 mos, HR 0.78, p = 0.02 both favouring ABCP) in the first line for advanced NSCLC patients without driver mutations [111]. Here, CD274 is linked to non-small cell lung carcinoma.